Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Engineered PB Graft for Haploidentical Transplant
NCT02960646Phase 1Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2017
- Primary completion
- Feb 2023
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD45RA-depleted peripheral blood stem cells in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and 4 more, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Incidence of treatment failure at 100 days. Started Jan 2017; status: completed.
02
Drugs
CD45RA-depleted peripheral blood stem cells
03
Conditions
acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic myeloid leukemia (CML)lymphoma
Beyond the preview
Go deeper on NCT02960646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02960646.